147 related articles for article (PubMed ID: 12858487)
1. [Controlled ovarian hyperstimulation (COH) and management of low-responder cases (HOO)].
Vladimirov IaK
Akush Ginekol (Sofiia); 2003; 42(3):23-6. PubMed ID: 12858487
[TBL] [Abstract][Full Text] [Related]
2. Poor responder protocols for in-vitro fertilization: options and results.
Loutradis D; Vomvolaki E; Drakakis P
Curr Opin Obstet Gynecol; 2008 Aug; 20(4):374-8. PubMed ID: 18660689
[TBL] [Abstract][Full Text] [Related]
3. [Premature ovarian failure: which protocols?].
Merviel P; Lourdel E; Boulard V; Cabry R; Claeys C; Oliéric MF; Sanguinet P; Brasseur F; Henri I; Copin H
Gynecol Obstet Fertil; 2008 Sep; 36(9):872-81. PubMed ID: 18703373
[TBL] [Abstract][Full Text] [Related]
4. Impact of coasting in patients undergoing controlled ovarian stimulation with the gonadotropin-releasing hormone antagonist cetrorelix.
Bahceci M; Ulug U; Tosun S; Erden HF; Bayazit N
Fertil Steril; 2006 May; 85(5):1523-5. PubMed ID: 16566935
[TBL] [Abstract][Full Text] [Related]
5. [Coasting and ovarian stimulation protocols in high-responder patients undergoing assisted conception].
Merviel P; Claeys C; Héraud MH; Lourdel E; Lanta S; Barbier F; Nasreddine A
Gynecol Obstet Fertil; 2005 Sep; 33(9):703-12. PubMed ID: 16129645
[TBL] [Abstract][Full Text] [Related]
6. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity.
Orvieto R; Meltzer S; Rabinson J; Zohav E; Anteby EY; Nahum R
Fertil Steril; 2008 Oct; 90(4):1294-6. PubMed ID: 18178197
[TBL] [Abstract][Full Text] [Related]
7. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation.
Mitwally MF; Casper RF
J Soc Gynecol Investig; 2004 Sep; 11(6):406-15. PubMed ID: 15350255
[TBL] [Abstract][Full Text] [Related]
9. [How to prevent completely ovarian hyperstimulation with GnRH-based stimulation protocols].
Kol S
Akush Ginekol (Sofiia); 2001; 40(4):36-41. PubMed ID: 11803870
[No Abstract] [Full Text] [Related]
10. Controlled ovarian hyperstimulation: a review for the non-ART patient.
Willis MY; Browne AS; Session DR; Spencer JB
Minerva Ginecol; 2011 Apr; 63(2):119-35. PubMed ID: 21508902
[TBL] [Abstract][Full Text] [Related]
11. Does day 3 luteinizing-hormone level predict IVF success in patients undergoing controlled ovarian stimulation with GnRH analogues?
Orvieto R; Meltzer S; Rabinson J; Gemer O; Anteby EY; Nahum R
Fertil Steril; 2008 Oct; 90(4):1297-300. PubMed ID: 18249369
[TBL] [Abstract][Full Text] [Related]
12. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
[TBL] [Abstract][Full Text] [Related]
13. New tools for optimizing endometrial receptivity in controlled ovarian hyperstimulation: aromatase inhibitors and LH/(mini)hCG.
de Ziegler D; Mattenberger C; Schwarz C; Ibecheole V; Fournet N; Bianchi-Demicheli F
Ann N Y Acad Sci; 2004 Dec; 1034():262-77. PubMed ID: 15731318
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors in ovulation induction.
Mitwally MF; Casper RF
Semin Reprod Med; 2004 Feb; 22(1):61-78. PubMed ID: 15083382
[TBL] [Abstract][Full Text] [Related]
15. Optimizing gonadotrophin-releasing hormone antagonist protocols.
Trew GH
Hum Fertil (Camb); 2002 Feb; 5(1):G13-6; discussion G16-8, G41-8. PubMed ID: 11939156
[TBL] [Abstract][Full Text] [Related]
16. [Onset and maintenance of the luteal phase with GnRH agonists or hCG in cycles under GnRH antagonists].
Olivennes F
J Gynecol Obstet Biol Reprod (Paris); 2004 Oct; 33(6 Pt 2):3S24-6. PubMed ID: 15643682
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and treatment of the poor responder.
Schoolcraft WB
Clin Obstet Gynecol; 2006 Mar; 49(1):23-33. PubMed ID: 16456340
[No Abstract] [Full Text] [Related]
18. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
Zhu YM; Gao HJ; He RH; Huang HF
Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
[TBL] [Abstract][Full Text] [Related]
19. GnRH analogs: depot versus short formulations.
Dal Prato L; Borini A; Cattoli M; Bonu MA; Sereni E; Flamigni C
Eur J Obstet Gynecol Reprod Biol; 2004 Jul; 115 Suppl 1():S40-3. PubMed ID: 15196715
[TBL] [Abstract][Full Text] [Related]
20. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation.
Malmusi S; La Marca A; Giulini S; Xella S; Tagliasacchi D; Marsella T; Volpe A
Fertil Steril; 2005 Aug; 84(2):402-6. PubMed ID: 16084881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
